USPTO Examiner HOPKINS SAMANTHA LAKE - Art Unit 1641

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18610978ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOFMarch 2024March 2026Abandon2421NoNo
18296452METHODS OF IMPROVING THE THERAPEUTIC INDEXApril 2023January 2026Abandon3321NoNo
18050845COMPOSITIONS AND METHODS FOR CO-POTENTIATION OF CD3 TO TREAT A VIRAL INFECTION AND INCREASE THE IMMUNE RESPONSE AGAINST A VIRAL ANTIGENOctober 2022October 2025Abandon3621NoNo
17823003Engineered Cytolytic ImmunecellAugust 2022August 2025Allow3500NoNo
17861177MODIFIED CD20 ANTIBODIES AND USES THEREOFJuly 2022April 2025Abandon3310NoNo
17849399HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLSJune 2022October 2025Allow4010NoNo
17842914Anti-claudin 6 Antibody and Antibody-drug ConjugateJune 2022October 2025Allow4010NoNo
17786265USES OF ANTI-TGF-BETA ANTIBODIES AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASESJune 2022February 2026Abandon4410NoNo
17778636MONOCLONAL ANTIBODIES THAT TARGET HUMAN CD47 PROTEINMay 2022December 2025Abandon4301NoNo
17777596A NOVEL ANTI-CD3/ANTI-EGFR BISPECIFIC ANTIBODY AND USES THEREOFMay 2022December 2025Abandon4301NoNo
17714847TREATMENTS FOR PRURIGO NODULARISApril 2022January 2026Allow4631YesNo
17764503AMIDE-LINKED, AMINOBENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOFMarch 2022December 2025Abandon4401NoNo
17762148ANTI-EPHA10 ANTIBODIES AND METHODS OF USE THEREOFMarch 2022November 2025Abandon4401NoNo
17631641FORMULATION COMPRISING ANTI-PD-1/HER2 BISPECIFIC ANTIBODY, METHOD FOR PREPARING SAME AND USE THEREOFJanuary 2022February 2026Allow4811YesNo
17572039TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1/LAG-3, PREPARATION METHOD THEREFOR, AND USE THEREOFJanuary 2022August 2025Abandon4401NoNo
17625925COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING IMMUNE CHECKPOINT INHIBITOR-RESISTANT CANCERJanuary 2022November 2025Abandon4610NoNo
17620290ANTI-CD3E/BCMA BISPECIFIC ANTIBODY AND USE THEREOFDecember 2021October 2025Allow4611NoNo
17552383ANTI-IL5R ANTIBODY FORMULATIONSDecember 2021July 2025Abandon4311NoNo
17596596Bispecific Chimeric Antigen ReceptorDecember 2021June 2025Abandon4201NoNo
17618922INHIBITION OF SIRP-GAMMA FOR CANCER TREATMENTDecember 2021December 2025Allow4830YesNo
17617046HIGH AFFINITY ANTI-CD3 ANTIBODIES, AND METHODS FOR THEIR GENERATION AND USEDecember 2021October 2025Allow4611NoNo
17616274ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS THAT TARGET TACIDecember 2021December 2025Allow4811YesNo
17616373ANTI-T CELL ANTIGEN-BINDING MOLECULE TO BE USED IN COMBINATION WITH CYTOKINE INHIBITORDecember 2021June 2025Abandon4201NoNo
17615832ANTIBODY AND BISPECIFIC ANTIBODY TARGETING LAG-3 AND USE THEREOFDecember 2021January 2026Allow4921YesNo
17613251ANTI-ROR1 / ANTI-CD3 BISPECIFIC BINDING MOLECULESNovember 2021March 2026Allow5121NoNo
17612877Uses of Radiation and Benzodiazepine Derivatives in Cancer TherapiesNovember 2021March 2026Allow5221NoNo
17530302ANTI-SIRPalpha MONOCLONAL ANTIBODIES AND USES THEREOFNovember 2021March 2025Allow4010YesNo
17522189ANTI-CD166 ANTIBODIES AND USES THEREOFNovember 2021May 2025Abandon4201NoNo
17609053HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOFNovember 2021October 2025Allow4711YesNo
17608204METHOD OF PRODUCING A RECOMBINANT PROTEINNovember 2021September 2025Abandon4610NoNo
17608056BIOLOGICAL BINDING MOLECULESNovember 2021March 2026Allow5211YesNo
17607641ALLOGENEIC CELL THERAPY OF B CELL MALIGNANCIES USING GENETICALLY ENGINEERED T CELLS TARGETING CD19October 2021September 2025Abandon4710NoNo
17452033FUSION PROTEIN OF SINGLE DOMAIN ANTIBODY AND PROCOAGULANTOctober 2021April 2025Allow4211NoNo
17499030Bispecific Antibody Compositions and Methods for Treating COVID-19October 2021July 2025Abandon4501NoNo
17290728HOMODIMER-TYPE BISPECIFIC ANTIBODY AGAINST HER2 AND CD3 AND USE THEREOFOctober 2021February 2026Abandon5821NoNo
17600904IMMUNE CELL CONTAINING TUMOR ANTIGEN RECOGNITION RECEPTOR AND APPLICATION THEREOFOctober 2021October 2025Abandon4811NoNo
17600300METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE IN COMPANION ANIMALSSeptember 2021June 2025Abandon4410NoNo
17599875ANTIBODIES AGAINST PROGRAMMED CELL DEATH PROTEIN 1 (PD1) AND USES THEREOFSeptember 2021July 2025Allow4510NoNo
17441960TREATMENT OF TAUPATHY DISORDERS BY TARGETING NEW TAU SPECIESSeptember 2021March 2025Abandon4201NoNo
17429090GLUCURONOXYLOMANNAN (GXM) RECEPTOR CHIMERIC ANTIGEN RECEPTORS AND USE THEREOFAugust 2021April 2025Allow4510NoNo
17422523HUMAN IMMUNODEFICIENCY VIRUS-SPECIFIC T CELL RECEPTORSJuly 2021April 2025Allow4511YesNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner HOPKINS, SAMANTHA LAKE - Prosecution Strategy Guide

Executive Summary

Examiner HOPKINS, SAMANTHA LAKE works in Art Unit 1641 and has examined 25 patent applications in our dataset. With an allowance rate of 56.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner HOPKINS, SAMANTHA LAKE's allowance rate of 56.0% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HOPKINS, SAMANTHA LAKE receive 1.04 office actions before reaching final disposition. This places the examiner in the 10% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HOPKINS, SAMANTHA LAKE is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +61.1% benefit to allowance rate for applications examined by HOPKINS, SAMANTHA LAKE. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 0% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Petition Practice

When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.